Why Kazia Therapeutics is Australia’s biotech shining star

Kazia Therapeutics share price has been driven by strong buying in their US-listed ADRs with the company’s market capitalisation moving from $75m to $200m since the Corporate Connect Research report was released. Corporate Connect biotech analyst Marc Sinatra updates the market post the ASX announcement by Kazia of further Paxalisib data.
Read More